TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nuwellis ( (NUWE) ) has issued an update.
On September 9, 2025, Nuwellis, Inc. announced that the National Institutes of Health (NIH) awarded a multi-year grant of approximately $3 million to its partner, Koronis Biomedical Technologies Corporation. This grant will expedite the development of Vivian™, a pediatric continuous renal replacement therapy device, and enhance the company’s software and firmware, potentially strengthening its market position.
The most recent analyst rating on (NUWE) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
Spark’s Take on NUWE Stock
According to Spark, TipRanks’ AI Analyst, NUWE is a Neutral.
Nuwellis’s overall stock score is primarily impacted by its financial struggles, including consistent losses and negative cash flows. Technical indicators suggest bearish momentum, and valuation metrics are unattractive due to negative earnings. While the earnings call and corporate events show some positive strategic initiatives, they are overshadowed by the immediate financial challenges.
To see Spark’s full report on NUWE stock, click here.
More about Nuwellis
Nuwellis, Inc. operates in the medical device industry, focusing on developing innovative solutions for fluid management in patients. The company is known for its products that cater to critical care, particularly in pediatric and adult patients requiring renal replacement therapies.
Average Trading Volume: 1,052,418
Technical Sentiment Signal: Sell
Current Market Cap: $4.41M
For an in-depth examination of NUWE stock, go to TipRanks’ Overview page.